Tags

Type your tag names separated by a space and hit enter

Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules.
Future Med Chem 2019; 11(19):2595-2620FM

Abstract

Idiopathic pulmonary fibrosis (IPF) is a type of chronic, progressive lung disease with unknown cause, which is characterized by increasing dyspnea and destruction of lung function with a high mortality rate. Evolving evidence demonstrated that the pathogenesis of IPF involved multiple signaling pathways such as inflammation, oxidative stress and fibrosis. However, drug discovery to prevent or revert IPF has been insufficient to cope with the development. Drug discovery targeting multiple links should be considered. In this review, we will brief the pathogenesis of IPF and discuss several small chemical entities toward the pathogenesis for IPF studied in animal models and clinical trials. The field of novel anti-IPF agents and the future directions for the prevention and treatment of IPF are detailed thoroughly discussed.

Authors+Show Affiliations

Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450017, China.Department of Pharmacy, Henan Provincial Hospital, Zhengzhou, Henan 451161, China.Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450017, China.Department of Chemistry, Graduate School of Science, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-Ku, Kyoto 606-8502, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31633402

Citation

Lv, Meng, et al. "Current Advances in Idiopathic Pulmonary Fibrosis: the Pathogenesis, Therapeutic Strategies and Candidate Molecules." Future Medicinal Chemistry, vol. 11, no. 19, 2019, pp. 2595-2620.
Lv M, Liu Y, Ma S, et al. Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. Future Med Chem. 2019;11(19):2595-2620.
Lv, M., Liu, Y., Ma, S., & Yu, Z. (2019). Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. Future Medicinal Chemistry, 11(19), pp. 2595-2620. doi:10.4155/fmc-2019-0111.
Lv M, et al. Current Advances in Idiopathic Pulmonary Fibrosis: the Pathogenesis, Therapeutic Strategies and Candidate Molecules. Future Med Chem. 2019;11(19):2595-2620. PubMed PMID: 31633402.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. AU - Lv,Meng, AU - Liu,Yan, AU - Ma,Shuli, AU - Yu,Zutao, PY - 2019/10/22/entrez KW - anti-IPF agents KW - idiopathic pulmonary fibrosis KW - pathogenesis SP - 2595 EP - 2620 JF - Future medicinal chemistry JO - Future Med Chem VL - 11 IS - 19 N2 - Idiopathic pulmonary fibrosis (IPF) is a type of chronic, progressive lung disease with unknown cause, which is characterized by increasing dyspnea and destruction of lung function with a high mortality rate. Evolving evidence demonstrated that the pathogenesis of IPF involved multiple signaling pathways such as inflammation, oxidative stress and fibrosis. However, drug discovery to prevent or revert IPF has been insufficient to cope with the development. Drug discovery targeting multiple links should be considered. In this review, we will brief the pathogenesis of IPF and discuss several small chemical entities toward the pathogenesis for IPF studied in animal models and clinical trials. The field of novel anti-IPF agents and the future directions for the prevention and treatment of IPF are detailed thoroughly discussed. SN - 1756-8927 UR - https://www.unboundmedicine.com/medline/citation/31633402/Current_advances_in_idiopathic_pulmonary_fibrosis:_the_pathogenesis,_therapeutic_strategies_and_candidate_molecules L2 - https://www.future-science.com/doi/full/10.4155/fmc-2019-0111?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -